

Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients

Chloé Pasin, Laura Villain, François Dufour, Daniel Commenges, Mélanie Prague, Rodolphe Thiébaut

► To cite this version:

Chloé Pasin, Laura Villain, François Dufour, Daniel Commenges, Mélanie Prague, et al.. Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients. Population Approach Group Europe, May 2018, Montreux, Switzerland. hal-01934340

HAL Id: hal-01934340 https://hal.inria.fr/hal-01934340

Submitted on 26 Nov 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Use of mathematical modeling for optimizing and adapting immunotherapy protocols in HIV-infected patients

C. Pasin^{1,2,3*}, L. Villain^{1,2,3*}, F. Dufour^{4,5}, D. Commenges^{1,2,3}, M. Prague^{1,2,3}, R. Thiébaut^{1,2,3}

¹INRIA Bordeaux Sud-Ouest, SISTM team, Talence, France
²Univ. Bordeaux, centre INSERM U1219 BPH, Bordeaux, France
³Vaccine Research Institute, Créteil, France
⁴INRIA Bordeaux Sud-Ouest, CQFD team, Talence, France
⁵INP, IMB, Bordeaux, France

PAGE meeting, Montreux, May 29 2018












Context

- Infection by the Human Immunodeficiency Virus (HIV) compromises the immune system: depletion of CD4⁺ T lymphocytes
- Combination antiretroviral therapies (cART) => improvment of patient's survival
- Some HIV-infected patients under cART are unable to recover normal CD4⁺ T cell levels
- Immune therapy using interleukine 7 (IL7) complements cART:
 - \blacktriangleright Phase I trials and observational studies \implies safety and beneficial effect of IL7 injections
 - ▶ Phase I/II human clinical trials (INSPIRE 1, 2 and 3 studies) \implies repeated cycles of 3 weekly IL7 injections help maintaining CD4⁺ T cells levels above 500 cells/µL [Levy et al. (2012), Thiébaut et al. 2016]

INSPIRE studies



- Total of 128 HIV-infected patients under cART with CD4 levels between 100-400 cells/ μ L and undetectable viral load for at least 6 months
- Cycles of 3 weekly IL7 injections of dose 20µg/kg (21 received dose 10 or 30)
- Regular measurements of CD4⁺ levels and proliferation marker Ki67
- Visits every three months. CD4 $^+$ levels < 550 cells $/\mu$ L \implies new cycle
- Total duration of the studies: between 12 and 24 months

Mechanistic model


Dynamics of CD4⁺ T lymphocytes, resting (R) or proliferating (P) [Thiébaut et al. (2014)]

- Parameters estimation with a population approach [Prague et al. (2013)]
- Identification of random effects on parameters λ and ρ
- IL-7 injection: effect on the proliferation rate π (differs for each injection within a cycle) [Jarne et al. (2017)]

$$\tilde{\pi}^{i} = \tilde{\pi}_{0} + \beta_{\pi}^{(n)} d_{i}^{0.25} \mathbb{1}_{\{t \in [t_{inj}^{i}, t_{inj}^{i} + \tau^{i}]\}}$$

d : injected dose, $n \in \{1,2,3\}$: injection of the cycle, τ : time of effect of the injection

Predictive ability of the model



- Main issue: criterion in the original protocol (decision to begin a new cycle when CD4 levels < 550 cells/µ) inadequate for some patients
- Next step: optimizing and adapting protocols of injections
- Aim: maintaining the CD4 levels > 500 cells/ μL without using too many injections

Pipeline



Estimation of the ODE parameters $\boldsymbol{\theta}$ using INSPIRE data

 \implies determination of a posterior distribution.

Inclusion of a new patient

Estimation of its individual parameters using the first observations.


Optimal control approach

- Use of optimal control theory to determine an optimal strategy of injections from a cost function.
- Stochasticity attributed to the biological process.

Bayesian approach

- Treatment decision is adapted at each new observation, by updating individual parameters estimation with MCMC algorithm.
- Stochasticity attributed to the uncertainty on the parameters estimation.

Assessment of the methods



Optimal control: proof-of-concept

- Objective: to determine actions (injection of not and choice of dose) at given time points over an horizon of time
 - \implies impulse control problem in the optimal control theory
- Two-steps method:
 - Developing an adapted mathematical model for the process: Piecewise Deterministic Markov model [Davis (1984)]
 - ▶ Using the theory of optimal control from [Costa et al. (2016)] to solve the impulse control problem by iteration of an integro-differential operator
 - computation of the optimal cost
 - determination of an optimal strategy of injections
 - comparison of the obtained optimal strategy to other clinical protocols

C. Pasin, F. Dufour, L. Villain, H. Zhang, R. Thiébaut. Controlling IL-7 injections in HIV-infected patients. To appear in *Bulletin of Mathematical Biology*

Optimal control: method


• Jump in the process : modification of parameter $\boldsymbol{\pi}$

- Deterministic: CD4 levels < 500 cells/ μ L \implies IL7 injection
- \blacktriangleright Random: stochastic time τ of effect of an IL7 injection

$$\tilde{\pi} = \tilde{\pi}_0 + \beta_{\pi}^{(n)} d^{0.25} \mathbb{1}_{\{t \in [t_{inj}, t_{inj} + \tau]\}}$$

- Cost function: combination of two criteria
 - Time spent with CD4 levels < 500 cells/ μ L
 - Number of injections realized
- Application of the method to determine the optimal strategy of 50 pseudo-patients on a reduced model:
 - 2 possible doses (10,20)
 - horizon of 1 year

Optimal control: results on 50 pseudo-patients




Category low not too low very low

Protocols. P1: 3-injections cycles. P2: 3-injections cycle then 2-injections cycles. P3: 2-injections cycles. P4: 2-injections cycle then 1-injection cycles. P5: 1-injection cycles.

- Development of a dynamic programming method to apply the theory of optimal control in a biological framework
- Intuitive optimal strategy: first cycles of 2 injections to increase the number of CD4⁺ then cycles of 1 injection to maintain the CD4 levels
- Limitations:
 - One year horizon only due to computational time
 - Main hypothesis: known individual parameters


Bayesian approach: pipeline




- ACI: Adaptive Criterion of Injection. Based on the predicted risk to have CD4 levels < 500 before the next visit (at 3 months)
- ATI: Adaptive Time of Injection. Based on the predicted time at which CD4 levels will reach 500.
- Both criteria: computed from estimated individual parameters, obtained thanks to observations

L. Villain, D. Commenges, C. Pasin, M. Prague, R. Thiébaut. Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts. *Statistics in Medicine* (under revision).


Bayesian approach: protocols comparison



Bayesian approach: protocols comparison



Bayesian approach: results on 150 pseudo-patients



Discussion

- Possibility to adapt the schedules of injections with both approaches
- Specific context: very good predictive ability of the model
 - Deterministic model
 - Only 2 markers needed
 - Short phase of learning
- Limitations of the optimal control approach:
 - Does not consider uncertainty on parameters
 - Requests large computing time
- But could be more adapted in a case where deterministic model fails at describing the biological process and stochastic model is needed
- Statistical approach: very powerful in this context
- Prospects:
 - Other biological applications
 - > Evaluation of the adaptive strategy on clinical outcomes in future trials

Acknowledgments

- INRIA SISTM / CQFD teams and other collaborators
- Vaccine Research Institute (Y Levy, JD Lelievre)
- INSPIRE Study group (JP Routy, I Sereti, M Fischl, P Ive, RF Speck, G D'offizi, S Casari, S Foulkes, V Natarajan, T Croughs, Jean-F Delfraissy, G Tambussi, MM Lederman)

